INTRODUCTION
Herpes simplex virus is the etiologic agent of a variety of significant human diseases. Herpes simplex virus 1 (HSV-1) causes common cold sores but also is responsible for most cases of viral encephalitis. Herpes keratitis, in which progressive scarring of the cornea occurs in response to HSV infection and reactivation, is the second most common cause of nontraumatic corneal blindness (49) . HSV-1 infections initiate at a mucosal surface where primary replication can lead to lesion formation. The virus also can establish acute and latent infections in sensory neurons innervating the primary site of infection and spread from there to the central nervous system. Thus, there are several stages at which a preexisting, protective immune response could intervene in HSV infection, each potentially different with regard to anatomical restrictions and relevant immune effector mechanisms. Determination of these sites of intervention and the immune components that provide protection at each site is crucial to development of a safe and effective vaccine to prevent HSV infection and disease.
Numerous approaches to vaccination against HSV have been developed, including inactivated and glycoprotein subunit vaccines and live attenuated virus or viral vectors (8) . A recent approach that combines the safety of an inactivated vaccine with the broad spectrum immunogenicity of live virus utilizes genetically engineered mutants of HSV that are live but impaired for replication, the so-called single cycle and replication-defective viruses. These replication-impaired mutants of HSV have been used to elicit immune responses in mice (13, 33, 34, 39) and guinea pigs (10, 29, 30) that are protective against HSV-1 and HSV-2 challenge, respectively. Viruses that contain a deletion in the UL29 (ICP8) gene express ␣, ␤, and ␥1 gene products in infected cells but cannot replicate their DNA (15) . Therefore, no progeny virions are produced to spread further within the host. We have demonstrated that immunization of mice with the ICP8
Ϫ replication-defective virus, d301, can reduce infection and prevent disease after corneal challenge with virulent HSV-1 (33) . Specifically, the immune response elicited by immunization reduces primary replication of challenge virus in the eye tissue and virus shedding from the corneal epithelium. Acute infection by challenge virus of the trigeminal ganglia (TG), which contain neurons innervating the cornea, is undetectable in immunized mice. Furthermore, latent infection of the TG by challenge virus is dramatically reduced, as demonstrated by explant reactivation (33) and by in situ hybridization of TG sections with a probe for latency associated transcripts (LAT) (34) . After challenge, no signs of keratitis or encephalitis develop in d301-immunized mice but are rampant in control mice immunized with uninfected cell lysate (33, 34) . Thus, protective effects have been identified at several stages in the pathogenesis of challenge virus infection and disease induction in mice immunized with replication-defective virus.
A variety of humoral and cellular effector mechanisms potentially could be responsible for the protective effects seen at each stage. We have demonstrated that subcutaneous immunization with d301 elicits HSV-specific neutralizing antibody and splenic T cell proliferative responses (33) . These responses and most of their protective effects are maintained for at least 7 months after immunization (34) . The IgG2a:IgG1 ratio of HSV-specific antibody indicates a Th1-type response is elicited by replication-defective virus (7), a conclusion which is supported by observation of an inhibitory effect of in vivo treatment with anti-IFN␥ antibody on induction of the IgG2a response (38) . Immunization with ICP8
Ϫ replication-defective virus also elicits CD8 ϩ cytolytic T cell responses to HSV-infected cells (6) . However, nothing is known about which components of the immune response elicited by these mutant viruses effect the dramatic protection seen against corneal challenge of mice with HSV-1. This information is essential to understanding the nature of protective, and protective versus pathologic, immune responses against HSV and may, in turn, further the development of safe and effective vaccines to prevent HSV infection. Here we define the contribution of replication-defective virus-immune serum antibody and T cell subsets to protection at several stages in the pathogenesis of HSV-1-mediated corneal infection and disease through a combination of serum passive transfer and in vivo depletion of CD4 ϩ and CD8 ϩ T cell subsets.
MATERIALS AND METHODS

Cells and viruses
The wild-type (wt) KOS1.1 (21) and mP (18) strains of HSV-1 were grown on Vero cell monolayers. The d301 strain is a replication-defective mutant of KOS1.1 bearing a deletion in the UL29 gene encoding ICP8 (14) . This virus expresses products of the ␣, ␤, and ␥1 gene classes in infected normal cells but propagation requires a cell line, S-2, that is stably transformed with the UL29 gene. Cell lysate stocks of all viruses were prepared as previously described (34) . The particle to plaque forming unit (PFU) ratio of mutant and wt virus preparations appears to be similar because cells in culture exposed to a given number of PFU of mutant virus contain equal levels of viral DNA compared with cells exposed to the same number of PFU of wt virus (15) . A portion of the wt virus stock was inactivated by exposure to UV light as previously described (33) .
Animals and inoculations
Female BALB/c mice, 6 weeks of age, were purchased from the National Cancer Institute (Fredericksburg, MD) or Taconic (Germantown, NY) and were acclimated 1 week before use. The mice were housed in accordance with institutional policies and National Institutes of Health guidelines (1) . For immunization, hair on the left rear flank of each mouse was trimmed and 2 ϫ 10 6 PFU of d301, KOS1.1, or equivalent amounts of UV-inactivated KOS1.1 or control cell lysate were inoculated by subcutaneous (s.c.) injection of a 20-l vol using a 26-g needle.
Corneal challenge with the mP strain of HSV-1 was carried out by inoculation of 2 ϫ 10 5 PFU/eye of virus onto the scarified cornea as described previously (33) .
Antibody and immune serum production
Rat hybridomas GK1.5 (ATCC TIB 207), specific for CD4, and 53-6.72 (ATCC TIB 105), specific for CD8, were expanded in vitro in DME plus 15% or RPMI plus 10% FCS, respectively, and transferred to McCoy's 5A medium (Gibco) plus 8% FCS. Antibody from supernatants was purified over a column of Sepharose 4B±protein G (Sigma). Protein-containing fractions were pooled, concentrated using microconcentrators (Amicon), and dialyzed at 4°C against PBS. Antibody concentration was adjusted to 1 mg/ml or 2 mg/ml with sterile PBS based on OD 280 spectrophotometric determination, and stored at Ϫ80°C.
Immune serum for passive transfer was generated by thrice immunizing groups of 9±11 mice s.c. in the flank at 1-month intervals with 2 ϫ 10 6 PFU of KOS1.1 wt virus, the d301 mutant virus, UV-inactivated KOS1.1 (1 ϫ 10 8 PFU/ml prior to inactivation), or an equivalent amount of control lysate. Blood was collected from the tail veins at 8, 10, and 13 days after the final immunization, and serum was harvested as described previously (33) . All samples within each group were pooled, passed through a 0.22-m filter (Gelman Science), and stored briefly at 4°C.
Passive transfer of immune serum
Groups of 6±8 female BALB/c mice, 6 weeks of age, were inoculated intraperitoneally (i.p.) with 0.3 ml hyperimmune serum 4 h prior to challenge and again 3 days after challenge. At 6 h after serum transfer, sera were collected from a cohort of recipient animals for determination of posttransfer serum neutralizing antibody titers. Sera were also collected from a cohort of control mice that had been directly immunized 1 month previously with the d301 virus.
T cell depletions
Groups of five mice immunized with d301 virus 1 month previously were injected i.p. with 0.3 ml of monoclonal antibodies GK1.5 or 53-6.72 at 1 mg/ml or a mixture of the antibodies at 2 mg/ml each in a total volume of 0.3 ml, on days Ϫ3, Ϫ1, ϩ3, ϩ7, ϩ11, and ϩ14 with respect to challenge. As controls, additional groups of immunized mice were injected with 0.3 ml of isotypematched normal rat IgG (1 mg/ml; Caltag) or PBS. Mice immunized with control lysate were injected with PBS.
Determination of neutralizing antibody titers
In T cell depletion studies, sera were collected prior to and 3, 6, or 9 days after challenge of a cohort of immunized mice treated with anti-CD4, anti-CD8, or control IgG. The titers of HSV-specific neutralizing antibody in all sera were determined by using a CPE inhibition assay as previously described (34) , except that mixtures without complement were incubated for 60 min and those with complement were incubated for 100 min.
FACS Analysis
Splenocytes from two mice treated on days Ϫ3 and Ϫ1 with anti-CD4 or anti-CD8 antibody and from two age-matched, untreated mice were collected and pooled. The mononuclear cell fraction was isolated by centrifugation over liquid separation medium (Organon Technika), washed, and resuspended at 2 ϫ 10 7 /ml in FACS buffer (PBS containing 1% (wt/vol) BSA, fraction V, and 0.1% sodium azide). To aliquots of 10 6 cells, 1 g FITCconjugated anti-CD8 (CT-CD8a), anti-CD4 (YTS191.1), or control IgG (all from Caltag), in 10-l vol, was added and incubated on ice for 30 min. Cells were washed three times and resuspended in FACS buffer, and the fluorescence intensity was determined by flow cytometric analysis. The percentage of lymphocytes positive for a given cell surface marker in depleted mice was compared with that in untreated mice to determine the efficacy of depletion.
Assays of acute and latent infection
Acute replication at various times after corneal challenge was assessed by viral titer in eye swabs as described previously (34) . Viral titers were determined by standard plaque assay (22) .
To assay for reactivating virus indicative of latent infection, TG were removed from animals 28 days after corneal challenge, minced, and placed in culture on Vero cell monolayers. Cultures showing no CPE after 10 days of incubation were collected, sonicated (Heat Systems), and placed onto fresh Vero cell monolayers to look for plaque formation.
Keratitis and encephalitis evaluation
Mice were observed daily in the period postchallenge for clinical signs of encephalitis: ruffled fur, hunched posture, ataxia, and anorexia. Keratitis scores, representing both severity and extent of disease, were determined for each eye of challenged mice as described previously (33) .
Histology
Twenty eight days after challenge, T cell-depleted mice and control IgG-treated mice were sacrificed. Eyes were dissected, fixed in formalin for 1 day, and transferred to 70% ethanol. Sections were obtained from paraffin-embedded tissue and stained with hematoxylin and eosin.
Statistical analyses
Fisher's exact test was used to determine the significance of differences in (1) the proportion of latently infected trigeminal ganglia between immunized mice depleted of CD4 ϩ or CD8 ϩ T cells and those treated with control IgG, and (2) the proportion of d301 serum recipients succumbing to challenge virus infection compared with wt and control serum recipients. The unpaired student's t test was used to compare geometric mean viral titers between groups on individual days, with no correction for multiple comparisons.
RESULTS
To investigate the role of various effector mechanisms in providing the protective immunity elicited by replication-defective mutant virus, we have chosen to allow the immune response to mutant virus to develop normally in immunized mice before we isolated or deleted a component of that response.
Serum passive transfer
In this study, we evaluated the role of serum antibody by passive transfer of immune serum to naive animals prior to challenge. An alternative approach, that of depleting mice of B cells prior to immunization by in vivo administration of anti-antibody, was not feasible because virus-specific T cell responses have been shown to develop abnormally under these conditions (44) . Prior to passive transfer, sera collected from mice immunized thrice with mutant, wt, or UV-inactivated virus had neutralizing titers equal to or greater than the titer of sera from control mice immunized once with mutant virus (preinjection, Table 1 ). At 6 h after serum transfer, titers of neutralizing antibody recovered from d301 mutant or wt serum recipients were essentially equivalent to the titer in control animals directly immunized with mutant virus (d301 virus-immunized, Table 1 ), indicating that serum neutralizing activity had been reconstituted to roughly physiologic levels at the time of challenge. Neutralizing activity recovered from the serum of mice injected with inactivated virus serum was lower than that of directly immunized animals. Passive transfer of immune serum was repeated 3 days after challenge to maintain serum antibody levels for at least 1 week postchallenge (20) .
Effect of serum antibody on primary replication of challenge virus. Titers of virus shed in the tear film on days 1 through 5 after challenge were equivalent in all adoptively transferred mice, regardless of the serum source (Fig. 1) . The titers of virus from mice directly immunized with mutant virus were significantly lower than in the serum recipients at all time points (P Ͻ 0.025 on day 1), reaching undetectable levels by 5 days after challenge (Fig. 1) . Thus, serum antibody at a titer equivalent to that in mice immunized once with mutant virus appeared to play little or no role in reducing replication of virus at the primary site of infection.
Effect of serum antibody on development of disease following challenge infection. In mice receiving wt virus serum, we observed no signs of disease after challenge virus infection. In mice receiving d301 serum, 6/8 mice showed ruffled fur by 5±7 days after challenge and 2/8 developed more distinct and protracted ruffling and also lost weight (data not shown). All mice in the groups receiving UV-wt serum or CL serum showed distinctly ruffled fur and were anorexic following challenge. Severity of symptoms correlated with eventual mortality; thus, all but one of the mice receiving CL or UV-wt serum succumbed to encephalitis (not significantly different; P ϭ 0.40), whereas only 2 of the mice receiving d301 serum and none of those receiving wt serum died (not significantly different; P ϭ 0.26; Fig. 2 ). This result indicates that passively transferred serum antibody, generated in mice immunized with the mutant virus and present in the serum at a level equivalent to a single immunization, had the capacity to protect most mice from development of fatal encephalitis but was not quite as effective as wt serum.
Mice directly immunized with mutant virus were protected from developing stromal keratitis following corneal challenge (Fig. 3) . In contrast, transfer of d301 or wt serum did not protect recipients from developing keratitis (Fig. 3) , indicating that HSV-specific serum antibody does not intervene in development of eye disease, at least with the amount transferred. The few mice receiving UV-wt or CL serum that survived more than 7 days after challenge also developed keratitis. Effect of serum antibody on latent infection. We determined the incidence of latent infection in the TG of surviving mice at 4 weeks after challenge. Reactivation of latent virus was detected in a cocultivation assay in only 24% of TG from mice immunized once with mutant virus prior to challenge, but was found in 88 and 100% of TG from mice receiving d301 or wt serum, respectively (P Ͻ 0.001; Table 2 ). Both TG from the surviving recipient of UV-wt serum also contained reactivating virus (Table  2) . Thus, serum antibody at the levels tested was not sufficient to protect against latent infection but did contribute to protection of mice by preventing development of fatal encephalitis. We do not yet know whether the relative lack of protective efficacy of serum from UVinactivated virus-immunized mice compared to mutant or wt virus-immune serum is a function of lower initial titer or of differences in affinity or epitope representation.
T cell depletion
The results of the serum transfer experiment suggested a primary role for T cells in mediating protection at various stages in the pathogenesis of challenge virus infection, leading us to investigate the contributions made by different T cell subsets. Adoptive transfer of T cells from immunized to naive mice would identify only the functional potential of a certain number of cells taken from an accessible lymphoid organ. Alternatively, mice genetically deficient in CD4 ϩ or CD8 ϩ T cells do not generate a normal distribution of remaining effectors after immunization (28) . Thus, to directly assess the contribution of virus-specific T cell subsets as mediators of protection, we immunized mice with replication-defective virus and then depleted them of CD4 ϩ or CD8 ϩ T cells by in vivo administration of anti-CD4 or -CD8 monoclonal antibody prior to challenge. Affinity-purified rat antibodies GK1.5 (anti-CD4) or 53-6.72 (anti-CD8) were injected i.p. into groups of mutant virus-immunized mice twice prior to corneal challenge, and every fourth day thereafter. Injection of isotype-matched, normal rat IgG or PBS into mutant virus-immunized mice served as a control for depletion, and s.c. inoculation of control lysate and subsequent injection of PBS served as a control for immu- nization. FACS analysis, using a different set of FITCconjugated anti-CD4 and anti-CD8 antibodies, of splenocytes from cohort animals revealed that on the day of challenge, mice injected with GK1.5 were 97% depleted of CD4 ϩ T cells and those injected with 53-6.72 were nearly 100% depleted of CD8 ϩ T cells (data not shown), in accord with previous depletion studies using these antibodies (19, 25, 28, 32, 37) . Though not as profound, depletion was still apparent 14 days after challenge (data not shown).
Effect of T cell depletion on primary replication in the eye. During the first 2 days after corneal challenge, the titers of virus shed into the tear film were similar whether or not mutant virus-immunized mice were depleted of CD4 ϩ and/or CD8 ϩ T cells (Fig. 4) . By 3 days after challenge, however, titers of virus in the eyes of mice treated with control Ig were significantly lower than those of mice depleted of CD4 ϩ T cells (P Ͻ 0.004) or double-depleted (P Ͻ 0.016). Four days after challenge, the differences in titer between control mice and those depleted of CD4 ϩ T cells or double-depleted were 1000-fold and 300-fold, respectively (P Ͻ 0.001 and P Ͻ 0.008, respectively). CD8-depleted mice showed no statistically significant increase in viral titer in the eye except at 4 days postchallenge in one of two experiments (data not shown). Thus, CD4
ϩ T cells appeared to play the major role in limiting the replication of challenge virus at the initial site of infection in the corneal epithelium, but this effect was not manifest for approximately 2 days.
Development of disease in mice depleted of T cell subsets. All mice that underwent T cell depletion showed no clinical signs of ill health during initial depletion or after challenge. Mice treated with both anti-CD4 and -CD8 antibodies also remained apparently healthy, corroborating the results of the serum adoptive transfer study which indicated that serum alone could confer significant protection against fatal encephalitis. Signs of encephalitis were observed in all control mice inoculated with uninfected cell lysate and treated with PBS, and mortality in this group was 80%.
Keratitis developed in all mice inoculated with control lysate and then challenged, but not in any of the eyes of mice immunized with mutant virus and treated with PBS or control IgG (Fig. 5) . Depletion of CD4 ϩ T cells from mutant virus-immunized mice did not diminish protection from disease. In contrast, several eyes from immunized mice depleted of CD8 ϩ T cells did develop focal keratitis which increased in severity with time (Fig. 5) . Two eyes from mice treated with antibody to both T cell subsets also developed mild keratitis, but not until nearly 3 weeks after challenge. Histologic examination of the affected corneas in CD8-depleted mice revealed a heavy infiltration of mononuclear cells and disruption of corneal architecture 28 days after challenge (Fig. 6A) . In contrast, corneas from CD4-depleted mice contained few mononuclear cells (Fig. 6B ) and were indistinguishable from corneal sections of immunized mice treated with control IgG (Fig. 6C) . Unimmunized mice that survived challenge virus infection showed severe keratitis at 28 days postchallenge (Fig. 6D) . These results suggest that the protection against development of keratitis afforded by immunization with mutant virus can be abrogated when only CD4
ϩ , HSV-immune T cells are present at the time of challenge. This observation in turn suggests that CD8 ϩ T cells elicited by immunization with mutant virus may regulate the immunopathologic potential of the CD4 ϩ T cells also elicited by immunization.
Incidence of latent infection in mice depleted of T cell subsets.
The presence of latent virus in TG of surviving mice was assessed by cocultivation assay 4 weeks after challenge. All ganglia from cell lysate-inoculated mice but only half of the ganglia from mutant virus-immunized mice treated with control IgG produced reactivating virus (Table 3 , experiment 1). In mice that were immunized and depleted of CD4 ϩ T cells, no protection from latent infection was observed because 10/10 ganglia produced reactivating virus (Table 3 , experiment 1). The incidence of latent infection was also increased in immunized mice treated with anti-CD8 antibody, but this result was not statistically significant in two independent experiments (Table 3 , experiments 1 and 2) whose reproducibility was supported by the observation of virtually identical eye titers in the two experiments (data not shown). These results suggest a role for CD4 ϩ T cells in reducing the incidence of latent infection as assessed by reactivation. Further studies are in progress to corroborate these observations by quantitation of challenge virus genomes in latently infected TG. Postdepletion serum titers of neutralizing antibody. We evaluated the titers of neutralizing antibody present in the serum of depleted mice over time after challenge to seek functional evidence of CD4 depletion and to determine whether loss of T help could have contributed to effects seen in CD4-depleted mice. After treatment and challenge, HSV-specific antibody titers rose in mice depleted of CD8 ϩ T cells and in control mice compared to prechallenge titer. In mice depleted of CD4 ϩ T cells, titers remained unchanged through 6 days after challenge and by 9 days after challenge had risen less than twofold compared to the titer of 1:93 seen prior to treatment and challenge (Table 4) . This result demonstrates an absence of helper function for antibody production in CD4-depleted mice. However, the small difference in antibody titers between CD8-depleted or control mice and CD4-depleted mice, taken together with the lack of protective activity of antibody seen upon passive serum transfer, was not likely to explain the loss of protection against establishment of latent infection in CD4-depleted mice.
DISCUSSION
We have studied components of the immune response elicited by immunization with a replication-defective HSV-1 mutant to determine the contributions of antibody and T cells to protection against challenge virus infection of the cornea. Serum antibody elicited by immunization with mutant virus principally prevents encephalitic infection of the CNS. CD4
ϩ T cells elicited in mice immunized with a replication-defective mutant strain of HSV-1 are required for the reduction of challenge virus infection of the corneal epithelium and appear to decrease latent infection in the trigeminal ganglion. CD8 ϩ T cells appear to play a role in preventing keratitis, possibly by regulating the immunopathologic potential of CD4 ϩ T cells. These studies were performed with normal mice in which the immune response to the mutant virus was permitted to develop naturally prior to isolation or removal of one component of it. As such, the immune response examined may be considered physiologic in magnitude and composition. The results of the serum transfer and T cell depletion studies are internally consistent and demonstrate that each component of the immune response induced by a live, replication-defective form of virus makes an important contribution to protection of the host at defined stages of challenge virus infection.
Our observation that the role of antibody was unequivocably confined to protection of the CNS is consistent with those of previous passive serum transfer and T cell suppression studies in mice which have shown an effect of antibody on neuronal spread of HSV (31) . However, they appear to conflict with several studies in which decreased severity of eye disease was seen after prophylactic treatment of mice with HSV-specific monoclonal antibodies (24, 43, 46) . It is possible that the serum concentration of monoclonal antibody achieved in those studies was much greater than that of our polyclonal response, which was equivalent to a single immunization with mutant virus, and that a higher antibody concentration may be necessary to accomplish protection against corneal infection and disease. Indeed, injection of 55 g of monoclonal antibody against HSV-1 gD decreases primary replication in the eye (2), but injection of lower doses does not (23) . HSV-specific neutralizing antibody has a half-life in serum of approximately 4 days (20) . Thus, the two injections of serum we performed would be expected to protect mice at least half-maximally over the period postchallenge in which virus replication in the eye and spread to the TG occurs (9) . Our results with serum passive transfer support the contention that the amount of antibody generated by a single immunization with replication-defective virus can protect mice from CNS disease, but does not exclude an additional role for T cells in CNS protection. Indeed, serum recipients were not protected as completely as mice depleted of either CD4 ϩ or CD8 ϩ T cells. Whether the passively transferred serum conferred protection against encephalitis due to its neutralizing activity is not known.
Numerous studies implicate CD4
ϩ T cells as mediators of an immunopathologic reaction to wt HSV infection (11, 27, 37) , or possibly a self-antigen revealed upon ocular herpetic infection (4), which results in development of keratitis in naive mice. In contrast, prior immunization with replication-defective virus protects mice from developing keratitis upon subsequent corneal challenge. Interestingly, fractionation of this protective immune response by CD8 ϩ T cell depletion revealed a potential for pathologic infiltration of some of the corneas, possibly mediated by the remaining CD4
ϩ T cell population. One possible interpretation is that CD4-mediated pathologic activity is normally regulated by the presence of immune CD8 ϩ T cells, suggesting an interplay between HSV-immune CD4 ϩ and CD8 ϩ T cells during response to challenge. Regulation of CD4 ϩ T cell activity by CD8 ϩ cells has previously been suggested based on the results of T cell depletion studies in naive mice responding to primary infection with HSV (37) . It is also possible that at least the more severe keratitis we observed in a few of the mice may have been mediated by newly generated CD8 ϩ T cells repopulating the animals as the effects of depletion waned. Regardless of the mechanism, protection against keratitis seen after immunization with mutant virus underscores the difference in response to challenge of a naive mouse and one immunized with replication-defective virus and suggests the importance of eliciting a balanced immune response through immunization that includes induction of CD8 ϩ T cells. CD4 ϩ T cells appear to be involved in decreasing replication of challenge virus in the cornea. This T cell subset predominates in corneal infiltrates of mice immunized with HSV-1 strain KOS prior to challenge (16) , and MHC class II has been noted on corneal Langerhans cells (41) and keratinocytes (12) within 48 h of infection with HSV, indicating that elements essential to CD4-mediated activity are present. Notably, the difference between CD4-depleted and control groups in viral replication in the eye was not apparent until Ͼ2 days after challenge. This delay probably represents the time required to activate memory cells and/or to recruit them to the scene of infection. Adoptively transferred, replicationdefective virus-specific CD4 ϩ T cells have also been shown to decrease primary replication of HSV-1 in the footpad more than CD8 ϩ T cells in a different model of HSV infection (6) .
The observation of an increased incidence of latent infection of the TG, as assessed by explant reactivation, in immunized mice depleted of CD4 ϩ T cells concurs with a prior observation that CD4-depleted mice previously immunized with HSV gD-1 show an increase in severity of neurologic disease after footpad challenge with HSV-2 (32) . Further studies will be necessary to determine whether CD4 ϩ T cells from replication-defective virus-immunized mice affect establishment of, or reactivation from, latency by challenge virus. In this regard, we have observed an 80-fold decrease in the number of neurons expressing latency-associated transcripts (LATs) in TG sections from mice immunized twice with mutant virus before challenge compared with mice immunized with control lysate before challenge (34) , suggesting that the immune response decreases establishment of latent infection by challenge virus. Depletion of CD4 ϩ T cells from naive mice also leads to increased latent infection of dorsal root ganglia after cutaneous infection (35) . The fact that primary or recurrent infections with HSV are more severe and frequent in T cell-suppressed patients and in AIDS patients with specific deletion of CD4 ϩ T cells (2,48) also supports the functional importance of CD4 ϩ T cells in controlling HSV infection and reactivation in humans. Depletion of CD8 ϩ T cells from naive mice has been shown to result in greater neuronal loss in dorsal root ganglia acutely infected with HSV (45), but our current study with immunized mice did not examine acute replication in the nervous system. CD8 ϩ T cells have also been seen to predominate during latency in the TG of naive A/J mice having undergone primary infection with HSV-1 (26) . Taken together, our observations and other reports describe the potential of both T cell subsets to operate in the nervous system and raise the intriguing possibility that the subsets may function differentially depending on neuroanatomic location or immune status.
The mechanism of T cell action in preventing acute or latent infection by HSV has not yet been elucidated but could include direct cytolytic effects and/or cytokine expression. Cytolysis of acutely infected neurons would be detrimental to the host and is unlikely to occur because of limited MHC molecule expression, but cytolysis of infected corneal cells as a means of controlling virus infection would be another possible scenario. HSV-specific, MHC class I-and class IIrestricted CTL have both been reported in mice (5, 37, 41) and humans (42, 49, 51). CD4
ϩ T cells predominate in the infiltrate of both cornea and TG of naive BALB/c mice infected with HSV-1, produce Th1 cytokines (4, 41) , and are the cause of immunopathology (38) . In naive A/J mice, increased levels of IFN␥ in the cornea (19) and IFN␥ and TNF in the TG (27) have been demonstrated coincident with CD8 ϩ T cell infiltration. This cytokine expression accompanies an inflammatory response with immunopathologic consequences that is paradoxically absent in replication-defective virus-immunized mice. In immunized mice, T cell-derived cytokines may be elaborated much more rapidly after onset of infection and may exert direct antiviral effects which make neighboring corneal cells refractory to infection, thereby inhibiting corneal spread of virus and establishment of latent infection in TG neurons and ultimately limiting the inflammatory response. Further work on antiviral mechanisms employed by protective, replication-defective virus-immune T cells will be necessary to distinguish among these possibilities. Such information will aid in identifying desirable vaccine-induced immune responses.
